[62], who documented objective responses (including decreased cellularity and stromal hyalinization) to larotrectinib in pediatric mesenchymal tumors harboring TPM3‐NTRK1 fusions, and Huang et al. Here, NTRK1 is linked to mesenchymal cell neoplasm.